Cargando…

Metals in Imaging of Alzheimer’s Disease

One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor th...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasnovskaya, Olga, Spector, Daniil, Zlobin, Alexander, Pavlov, Kirill, Gorelkin, Peter, Erofeev, Alexander, Beloglazkina, Elena, Majouga, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730413/
https://www.ncbi.nlm.nih.gov/pubmed/33276505
http://dx.doi.org/10.3390/ijms21239190
_version_ 1783621678550482944
author Krasnovskaya, Olga
Spector, Daniil
Zlobin, Alexander
Pavlov, Kirill
Gorelkin, Peter
Erofeev, Alexander
Beloglazkina, Elena
Majouga, Alexander
author_facet Krasnovskaya, Olga
Spector, Daniil
Zlobin, Alexander
Pavlov, Kirill
Gorelkin, Peter
Erofeev, Alexander
Beloglazkina, Elena
Majouga, Alexander
author_sort Krasnovskaya, Olga
collection PubMed
description One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor therapy, delaying the progression of the disease. However, clinically used radiopharmaceuticals based on (11)C and (18)F are synchrotron-dependent and short-lived. The design of new metal-containing radiopharmaceuticals for AD visualization is of interest. The development of coordination compounds capable of effectively crossing the blood-brain barrier (BBB) requires careful selection of a ligand moiety, a metal chelating scaffold, and a metal cation, defining the method of supposed Aβ visualization. In this review, we have summarized metal-containing drugs for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer’s disease. The obtained data allow assessing the structure-ability to cross the BBB ratio.
format Online
Article
Text
id pubmed-7730413
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77304132020-12-12 Metals in Imaging of Alzheimer’s Disease Krasnovskaya, Olga Spector, Daniil Zlobin, Alexander Pavlov, Kirill Gorelkin, Peter Erofeev, Alexander Beloglazkina, Elena Majouga, Alexander Int J Mol Sci Review One of the hallmarks of Alzheimer’s disease (AD) is the deposition of amyloid plaques in the brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the pathology. Timely diagnostics of amyloid formations allows identifying AD at an early stage and initiating inhibitor therapy, delaying the progression of the disease. However, clinically used radiopharmaceuticals based on (11)C and (18)F are synchrotron-dependent and short-lived. The design of new metal-containing radiopharmaceuticals for AD visualization is of interest. The development of coordination compounds capable of effectively crossing the blood-brain barrier (BBB) requires careful selection of a ligand moiety, a metal chelating scaffold, and a metal cation, defining the method of supposed Aβ visualization. In this review, we have summarized metal-containing drugs for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer’s disease. The obtained data allow assessing the structure-ability to cross the BBB ratio. MDPI 2020-12-02 /pmc/articles/PMC7730413/ /pubmed/33276505 http://dx.doi.org/10.3390/ijms21239190 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Krasnovskaya, Olga
Spector, Daniil
Zlobin, Alexander
Pavlov, Kirill
Gorelkin, Peter
Erofeev, Alexander
Beloglazkina, Elena
Majouga, Alexander
Metals in Imaging of Alzheimer’s Disease
title Metals in Imaging of Alzheimer’s Disease
title_full Metals in Imaging of Alzheimer’s Disease
title_fullStr Metals in Imaging of Alzheimer’s Disease
title_full_unstemmed Metals in Imaging of Alzheimer’s Disease
title_short Metals in Imaging of Alzheimer’s Disease
title_sort metals in imaging of alzheimer’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730413/
https://www.ncbi.nlm.nih.gov/pubmed/33276505
http://dx.doi.org/10.3390/ijms21239190
work_keys_str_mv AT krasnovskayaolga metalsinimagingofalzheimersdisease
AT spectordaniil metalsinimagingofalzheimersdisease
AT zlobinalexander metalsinimagingofalzheimersdisease
AT pavlovkirill metalsinimagingofalzheimersdisease
AT gorelkinpeter metalsinimagingofalzheimersdisease
AT erofeevalexander metalsinimagingofalzheimersdisease
AT beloglazkinaelena metalsinimagingofalzheimersdisease
AT majougaalexander metalsinimagingofalzheimersdisease